InMed Pharmaceuticals Inc. (TSE:IN – Get Free Report) shares were down 1.6% during trading on Monday . The stock traded as low as C$4.13 and last traded at C$4.19. Approximately 17,035 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 29,552 shares. The stock had previously closed at C$4.26.
InMed Pharmaceuticals Stock Performance
The company has a market cap of C$33.73 million and a PE ratio of -2.77. The company has a debt-to-equity ratio of 8.48, a quick ratio of 1.45 and a current ratio of 2.13. The business’s 50-day moving average price is C$4.19.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
See Also
- Five stocks we like better than InMed Pharmaceuticals
- Why Invest in 5G? How to Invest in 5G Stocks
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
